Clinical Trials
31 trialsIACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Nab-PIPAC
University Hospital, Geneva
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
National Cancer Institute (NCI)
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
GOG Foundation
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
City of Hope Medical Center
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
GOG Foundation
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
GOG Foundation
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
GOG Foundation
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)